News from boehringer ingelheim pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 08, 2014, 13:30 ET

New Data Show Idarucizumab* Reverses Anticoagulant Effects of Dabigatran (PRADAXA®) in Middle-Aged, Elderly and Renally Impaired Volunteers

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced phase I data that showed administration of investigational idarucizumab in healthy...

Nov 18, 2014, 10:00 ET

New Data Show Idarucizumab* Restores Wound-Site Formation of Fibrin, a Key Component of Blood Clotting, in Healthy Volunteers Given Pradaxa® (dabigatran etexilate mesylate)

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced phase I study sub-analyses showing that its investigational antidote idarucizumab...

Nov 18, 2014, 10:00 ET

Interim Data Reinforce Safety and Effectiveness of Pradaxa® (dabigatran etexilate mesylate) versus Warfarin in Routine Care of Patients with Non-valvular Atrial Fibrillation

Brigham and Women's Hospital and Boehringer Ingelheim Pharmaceuticals, Inc. today announced interim findings from an analysis of two health...

Nov 17, 2014, 10:00 ET

U.S. Department of Defense Study Supports Favorable Benefit-Risk Profile of Pradaxa® (dabigatran etexilate mesylate) for Reducing Stroke Risk in Non-valvular Atrial Fibrillation

Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a U.S. Department of Defense cohort analysis of the Military Health System...

Nov 10, 2014, 08:00 ET

New Real-World Safety and Efficacy Data on Pradaxa® (dabigatran etexilate mesylate) to be Presented at American Heart Association Scientific Sessions

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that two separate comparative analyses evaluating the safety and efficacy of...

Nov 10, 2014, 08:00 ET

Boehringer Ingelheim Initiates U.S. Sites in First-Ever Global Phase III Trial of Investigational Antidote in Patients Taking PRADAXA® (dabigatran etexilate mesylate)

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced the initiation of U.S. sites of the RE-VERSE AD™ trial (NCT02104947), a phase...

Nov 03, 2014, 10:00 ET

Boehringer Ingelheim Announces U.S. Filing Acceptance of New Drug Application for Spiriva® Respimat® (tiotropium bromide) Inhalation Spray for the Treatment of Asthma

 Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for...

Oct 27, 2014, 09:45 ET

Boehringer Ingelheim Presents Data for the Co-Administration of Two Approved Products for COPD Patients

 Boehringer Ingelheim today presented data from the ANHELTO™ 1&2 studies (NCT01694771/NCT01696058) that evaluated the...

Oct 15, 2014, 18:55 ET

FDA Approves Boehringer Ingelheim's OFEV® (nintedanib) as First Kinase Inhibitor to Treat Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved OFEV® (nintedanib)...

Oct 08, 2014, 08:00 ET

New COPD Maintenance Treatment Striverdi® Respimat® (olodaterol) Inhalation Spray Now Available in U.S. Pharmacies

 Boehringer Ingelheim today announced that Striverdi® Respimat® (olodaterol) Inhalation Spray 5 mcg is now available by prescription...

Sep 29, 2014, 08:00 ET

Head-to-head Phase III trial demonstrates superior progression-free survival of afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung

Phase III data from Boehringer Ingelheim's LUX-Lung 8 trial, the first study to evaluate the superiority of afatinib versus erlotinib in patients...

Sep 25, 2014, 08:00 ET

Boehringer Ingelheim Announces FDA Approval of Spiriva® Respimat® (tiotropium bromide) Inhalation Spray for the Maintenance Treatment of COPD

 Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved Spiriva®...

Sep 10, 2014, 10:00 ET

To Mark Pulmonary Fibrosis Awareness Month, Boehringer Ingelheim Announces Discovery Channel Documentary on Idiopathic Pulmonary Fibrosis

 In support of Pulmonary Fibrosis Awareness Month, Boehringer Ingelheim Pharmaceuticals, Inc., announces the airing of Every Breath Counts:...

Sep 09, 2014, 08:30 ET

New Analysis of Phase III Trials Examines the Impact of Boehringer Ingelheim's IPF Therapy Nintedanib on Lung Function Decline Based on Patients' Baseline Severity

A pre-specified, pooled subgroup sensitivity analysis from the two identically designed Phase III INPULSIS™ trials, presented today at the...

Sep 08, 2014, 13:25 ET

Boehringer Ingelheim Presents Pivotal Phase III Data for the Investigational Fixed-Dose Combination of Tiotropium + Olodaterol in COPD

Boehringer Ingelheim today presented the first data from the pivotal Phase III TONADO™ 1&2 studies (NCT01431274/NCT01431287) for the...

Sep 08, 2014, 11:48 ET

New Phase III Study Shows Investigational Tiotropium Improves Lung Function in Adolescent Patients with Symptomatic Asthma

 Boehringer Ingelheim today presented new data from the company's Phase III trial program (UniTinA-asthma®) evaluating tiotropium in...

Sep 02, 2014, 08:18 ET

ESC Hot Line: Data Reports NVAF Patients Taking Pradaxa® (dabigatran etexilate mesylate) Experienced Slower Decline in Kidney Function Compared to Those on Warfarin

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a new post-hoc sub-analysis of the pivotal phase III RE-LY® trial...

Aug 26, 2014, 09:00 ET
Boehringer Ingelheim logo.  (PRNewsFoto/Eli Lilly and Company)

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

 Jardiance® (empagliflozin) tablets are now available by prescription in pharmacies across the United States, including Walgreens, Rite...

Aug 25, 2014, 08:00 ET

Pradaxa® (dabigatran etexilate mesylate) Data to be Presented at European Society of Cardiology Congress 2014

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that data from nine company-sponsored Pradaxa® (dabigatran etexilate mesylate)...

Aug 19, 2014, 10:00 ET

Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD

 Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for...